145 related articles for article (PubMed ID: 32302762)
21. Use of keratin 35betaE12 as an adjunct in the diagnosis of mammary intraepithelial neoplasia-ductal type--benign and malignant intraductal proliferations.
Moinfar F; Man YG; Lininger RA; Bodian C; Tavassoli FA
Am J Surg Pathol; 1999 Sep; 23(9):1048-58. PubMed ID: 10478664
[TBL] [Abstract][Full Text] [Related]
22. Intraductal carcinoma (ductal carcinoma in situ) of the breast. A comparison of pure noninvasive tumors with those including different proportions of infiltrating carcinoma.
Moriya T; Silverberg SG
Cancer; 1994 Dec; 74(11):2972-8. PubMed ID: 7954261
[TBL] [Abstract][Full Text] [Related]
23. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
[TBL] [Abstract][Full Text] [Related]
24. Apocrine intraductal carcinoma in situ in nevus sebaceus: two case reports.
Llamas-Velasco M; Requena L; Podda M; Weidenthaler-Barth B; Rütten A
J Cutan Pathol; 2014 Dec; 41(12):944-9. PubMed ID: 25302933
[TBL] [Abstract][Full Text] [Related]
25. Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast.
Solin LJ; Fourquet A; McCormick B; Haffty B; Recht A; Schultz DJ; Barrett W; Fowble BL; Kuske R; Taylor M
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):3-9. PubMed ID: 8083125
[TBL] [Abstract][Full Text] [Related]
26. The angiotensin receptor blocker, Losartan, inhibits mammary tumor development and progression to invasive carcinoma.
Coulson R; Liew SH; Connelly AA; Yee NS; Deb S; Kumar B; Vargas AC; O'Toole SA; Parslow AC; Poh A; Putoczki T; Morrow RJ; Alorro M; Lazarus KA; Yeap EFW; Walton KL; Harrison CA; Hannan NJ; George AJ; Clyne CD; Ernst M; Allen AM; Chand AL
Oncotarget; 2017 Mar; 8(12):18640-18656. PubMed ID: 28416734
[TBL] [Abstract][Full Text] [Related]
27. A simple model of breast carcinoma growth may provide explanations for observations of apparently complex phenomena.
Kopans DB; Rafferty E; Georgian-Smith D; Yeh E; D'Alessandro H; Moore R; Hughes K; Halpern E
Cancer; 2003 Jun; 97(12):2951-9. PubMed ID: 12784329
[TBL] [Abstract][Full Text] [Related]
28. HER2 status in pure ductal carcinoma in situ and in the intraductal and invasive components of invasive ductal carcinoma determined by fluorescence in situ hybridization and immunohistochemistry.
Park K; Han S; Kim HJ; Kim J; Shin E
Histopathology; 2006 May; 48(6):702-7. PubMed ID: 16681686
[TBL] [Abstract][Full Text] [Related]
29. The PPARγ agonist efatutazone delays invasive progression and induces differentiation of ductal carcinoma in situ.
Ory V; Kietzman WB; Boeckelman J; Kallakury BV; Wellstein A; Furth PA; Riegel AT
Breast Cancer Res Treat; 2018 May; 169(1):47-57. PubMed ID: 29350308
[TBL] [Abstract][Full Text] [Related]
30. Endocrine ductal carcinoma in situ (E-DCIS) of the breast: a form of low-grade DCIS with distinctive clinicopathologic and biologic characteristics.
Tsang WY; Chan JK
Am J Surg Pathol; 1996 Aug; 20(8):921-43. PubMed ID: 8712293
[TBL] [Abstract][Full Text] [Related]
31. [The treatment of ductal carcinoma in situ (DCIS) of the breast].
Westenberg AH; Rutgers EJ; Peterse JL; Hendriks JH; Beex LV; van Tienhoven G
Ned Tijdschr Geneeskd; 2003 Nov; 147(44):2157-61. PubMed ID: 14626831
[TBL] [Abstract][Full Text] [Related]
32. Effective treatment of ductal carcinoma in situ with a HER-2- targeted alpha-particle emitting radionuclide in a preclinical model of human breast cancer.
Yoshida T; Jin K; Song H; Park S; Huso DL; Zhang Z; Liangfeng H; Zhu C; Bruchertseifer F; Morgenstern A; Sgouros G; Sukumar S
Oncotarget; 2016 May; 7(22):33306-15. PubMed ID: 27119227
[TBL] [Abstract][Full Text] [Related]
33. Five year outcome of 145 patients with ductal carcinoma in situ (DCIS) after accelerated breast radiotherapy.
Ciervide R; Dhage S; Guth A; Shapiro RL; Axelrod DM; Roses DF; Formenti SC
Int J Radiat Oncol Biol Phys; 2012 Jun; 83(2):e159-64. PubMed ID: 22579378
[TBL] [Abstract][Full Text] [Related]
34. Clinical Trials for Ductal Carcinoma In Situ of the Breast.
Han MS; Khan SA
J Mammary Gland Biol Neoplasia; 2018 Dec; 23(4):293-301. PubMed ID: 30206737
[TBL] [Abstract][Full Text] [Related]
35. Invasive ductal carcinoma with coexisting ductal carcinoma in situ (IDC/DCIS) versus pure invasive ductal carcinoma (IDC): a comparison of clinicopathological characteristics, molecular subtypes, and clinical outcomes.
Goh CW; Wu J; Ding S; Lin C; Chen X; Huang O; Chen W; Li Y; Shen K; Zhu L
J Cancer Res Clin Oncol; 2019 Jul; 145(7):1877-1886. PubMed ID: 31089799
[TBL] [Abstract][Full Text] [Related]
36. Feasibility of the Less Is More Approach in Treating Low-Risk Ductal Carcinoma In Situ Diagnosed on Core Needle Biopsy: Ten-Year Review of Ductal Carcinoma In Situ Upgraded to Invasion at Surgery.
Podoll MB; Reisenbichler ES; Roland L; Bruner A; Mizuguchi S; Sanders MAG
Arch Pathol Lab Med; 2018 Sep; 142(9):1120-1126. PubMed ID: 29582675
[TBL] [Abstract][Full Text] [Related]
37. Expression of maspin is up-regulated during the progression of mammary ductal carcinoma.
Umekita Y; Yoshida H
Histopathology; 2003 Jun; 42(6):541-5. PubMed ID: 12786889
[TBL] [Abstract][Full Text] [Related]
38. Ultrasound Image Classification of Ductal Carcinoma In Situ (DCIS) of the Breast: Analysis of 705 DCIS Lesions.
Watanabe T; Yamaguchi T; Tsunoda H; Kaoku S; Tohno E; Yasuda H; Ban K; Hirokaga K; Tanaka K; Umemoto T; Okuno T; Fujimoto Y; Nakatani S; Ito J; Ueno E
Ultrasound Med Biol; 2017 May; 43(5):918-925. PubMed ID: 28242086
[TBL] [Abstract][Full Text] [Related]
39. Management of ductal carcinoma in situ with nipple discharge. Intraductal spreading of carcinoma is an unfavorable pathologic factor for breast-conserving surgery.
Ohuchi N; Furuta A; Mori S
Cancer; 1994 Aug; 74(4):1294-302. PubMed ID: 8055451
[TBL] [Abstract][Full Text] [Related]
40. Current controversies in the treatment of ductal carcinoma in situ of the breast.
Franceschini G; Terribile D; Magno S; Fabbri C; D'Alba P; Chiesa F; Di Leone A; Scafetta I; Masetti R
Ann Ital Chir; 2008; 79(3):151-5. PubMed ID: 18958961
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]